Navigation Links
inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007
Date:2/28/2008

ked securities. Consistent with the company's

investment policy guidelines, the vast majority of holdings within CSCP

held by the company had AAA/Aaa credit ratings at the time of purchase.

With the liquidity issues experienced in the global credit and capital

markets, the CSCP experienced other than temporary losses resulting in

a change in the net asset value per share from its $1 par value. The

other than temporary impairment loss was adjusted to exclude this

charge for fourth quarter and full year 2007 results.

-- Acquisition-related incentive: The fourth quarter and full-year

periods for 2007 and 2006 exclude $1.5 million of income and $3.5

million of expense, respectively, of acquisition-related incentives

arising from a pre-acquisition liability related to the acquisition of

inVentiv Communications, Inc. (the former "inChord Communications").

In connection with the inVentiv Communications, Inc. acquisition, the

Company assumed a $7.5 million existing liability (out of a potential

$15.0 million liability) on inVentiv Communications, Inc.'s balance

sheet relating to certain performance thresholds over a three-year

period from 2005 through 2007. The Company has monitored these

performance thresholds on a quarterly basis, and as of December 31,

2006, $3.5 million of additional non-recurring expense was recorded as

a result of management's evaluation of new business wins during 2006

and the strengthened outlook for inVentiv Communications, Inc.'s

business during 2007. Based on the final 2005-2007 three-year

performance results of inVentiv Communications, Inc., a reversal of

$1.5 million was recorded to this liability and as additional income in

2007. The acquisition-related incentives were adjusted to exclude these

adjustments in t
'/>"/>

SOURCE inVentiv Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. inVentiv Health Ranked #17 by Training Magazine in its 2008 List of Top 125 Training Companies
2. inVentiv Health to Announce Fourth Quarter and Full Year 2007 Results and Conduct Conference Call on Thursday, February 28th
3. inVentiv Health Provides Updated Information on December 11th Investor Day
4. inVentiv Health Creates Client Development and Integration Team
5. inVentiv Health to Present at the 2007 Credit Suisse Healthcare Conference
6. inVentiv Health Launches Fourth Business Segment: inVentiv Patient Outcomes
7. inVentiv Health to Announce Third Quarter Results and Conduct Conference Call on Wednesday, November 7, 2007
8. inVentiv Health to Present at the 20th Annual Bear Stearns Healthcare Conference
9. Crdentia Selected by Leading Staffing Vendor to Provide Health Care Staffing Services to One of the Largest Hospital Chains in the U.S.
10. Former Blue Cross/Blue Shield Account Manager Sentenced for Health Care Fraud Scheme, Tax Evasion
11. UCLA launches network to study health care disparities affecting minorities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)...c. 2 VirtualScopics, Inc...tative imaging for clinical,trials, today announc...,compared to $14.7 million at the same time a year...lculates backlog as the amount remaining to be,re...ration of the studies,included within the backlog...
(Date:12/2/2008)...ew Report Finds Many Cite Prevention, Shedding, or...2 A New Center for Stat...how states are balancing retiree health care plans...ree Health Care in the American States examines h... retiree health care benefits to central human res...
(Date:12/2/2008)... Patients treated with radiation prior to surger...of cancer recurrence and better overall survival r...The report examined a treatment called neoadjuvant... limit the spread of cancer, before surgery to rem...motherapy and/or radiation. , Neoadjuvant thera...
(Date:12/2/2008)...A new report from the Institute of Medicine propos...workloads to decrease the chances of fatigue-relat...ronment for these doctors in training. The report...rk hours from the maximum average of 80 per week s...al Education (ACGME) in 2003, but rather reduces t...
Breaking Medicine News(10 mins):Health News:VirtualScopics Backlog Rises to a Record $27 Million 2Health News:VirtualScopics Backlog Rises to a Record $27 Million 3Health News:States View Limits on Retiree Health Benefits 2Health News:Revised hours and workloads for medical residents needed to prevent 2Health News:Revised hours and workloads for medical residents needed to prevent 3
...ican Journal of Preventive Medicine says that ther...sease. These conclusions were arrived at by resea...ealth at the Centers for Disease Control and Preve...pondents who took part in the 1999-2002 Behavioral...
...evealed that a version of the Viagra pill meant fo...nction market is much larger when compared to that...o develop a pill for that, according to Ellis. The...an has to be factored in for developing the pill, ...
...ents with psychiatric disorders. The number of pat... by 12% in the past 4 years. This shows us that ...ties. According to the Australian Institute of He... number of patients attending to specialized psych...
...of Camembert cheese with the microorganism E.coli,...d from supply due to potential risk of food poison...ning notice against consumption of this cheese. A...etes a bacterial toxin named verocytotoxins has be...
Other Medicine News:Health News:Community hospitals inundated with Psychiatric care cases (12%) 2
(Date:12/1/2008)...swire/ -- New research has found that the availabi... (CT) scanner in an emergency room can significant...ve a potentially life-saving treatment. Results of...r (NSMC)-Salem Hospital in Salem, Mass., will be p...ogical Society of North America (RSNA). , , ...
(Date:12/1/2008)...e-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq...e of the world,s leading medical journals, results...or, experimental compound tasimelteon (VEC-162). ... "Melatonin agonist tasimelteon (VEC-162) for tran...sed controlled multicentre trials." Results are re...
(Date:12/1/2008)... S*BIO Pte Ltd today announced the initiation of a...orally-active JAK2 inhibitor, in leading medical c...pathic myelofibrosis (CIMF). , , The trial...ty of SB1518 in patients with CIMF and is expected...the study will assess the safety profile and evalu...
(Date:12/1/2008)...reated With ENB-0040 at Children,s Hospital, Healt... Dec. 1 Enobia Pharma, an emerging...vel therapeutics for serious bone disorders, today...inical program for hypophosphatasia was dosed. Eno...RT) with ENB-0040 for the treatment of this rare a...
Breaking Medicine Technology:Portable CT Increases Chance of Stroke Survival and Recovery 2Portable CT Increases Chance of Stroke Survival and Recovery 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5Roseland Medical Center Hosts Recognition Ceremony and Open House 16882 1CDC and Retail Health Clinic Leaders Explore Improving Prevention Surveillance and Emergency Response 16880 1CDC and Retail Health Clinic Leaders Explore Improving Prevention Surveillance and Emergency Response 16880 2Calorie restricted diet prevents pancreatic inflammation and cancer 16879 1Calorie restricted diet prevents pancreatic inflammation and cancer 16879 2Marriage for a New World 16877 1Marriage for a New World 16877 2
... Cytogen,Corporation (NASDAQ: CYTO) today reported...the 2007 Annual Meeting of the American,Associatio...ngeles,California April 14-18, 2007. The AACR abs...ate novel approaches to drug,discovery and develop...(TM) (Antigen-Binding pepTIDES) and oral drug deli...
...A Pharmaceuticals,Inc. (Nasdaq: ACAD), a biopharma...o fuel drug discovery and clinical,development of ...ers, today announced that the company will present...ia Research, held from,March 28 through April 1, 2...will cover ACADIA,s two schizophrenia programs and...
Other Medicine Technology:Preclinical Data on Cytogen's Technology to be Reported at the AACR,Annual Meeting 2Preclinical Data on Cytogen's Technology to be Reported at the AACR,Annual Meeting 3Preclinical Data on Cytogen's Technology to be Reported at the AACR,Annual Meeting 4ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 2ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 3ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 4ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 5
Stainless steel construction to withstand sterilization modalities (EtO) Wide angle of view
Inquire
ENDOlap™ laparoscopes provide excellent image linearity and flatness of field.
The Fujinon's R410 laparoscope is the first to bring a 410,000 pixel CCD to the end of the scope. Superior imaging and color replication, along with a unique lens washing capability make the R410 the
Medicine Products: